SGP — SpyGlass Pharma, Inc. Common Stock stock price, charts and financials

Latest market price

29.33

+0.73+2.55%

Overview Short InterestFilings

SGPQT82SpyGlass Pharma, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

29.33+2.55%

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MESO+3.19%$14.87 FTRE+1.55%$20.28 NKTR+1.45%$68.36 GHRS+3.50%$28.72 RAPP+1.35%$41.95 AGIO+2.00%$33.61 ZBIO-1.08%$31.97 GPCR-1.13%$35.10

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	33.43M	Perf Week	7.40%

Market Cap	980.60M	Forward P/E	-	EPS next Y	-2.81	Insider Trans	-	Shs Float	13.95M	Perf Month	13.51%

Enterprise Value	748.60M	PEG	-	EPS next Q	-0.66	Inst Own	127.23%	Short Float	3.28%	Perf Quarter	61.15%

Income	-40.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	9.52	Perf Half Y	9.44%

Sales	0.00	P/B	4.23	EPS next Y	-12.63%	ROA	-23.03%	Short Interest	1.10M	Perf YTD	22.21%

Book/sh	6.94	P/C	4.19	EPS next 5Y	-	ROE	-75.64%	52W High	32.44 -9.59%	Perf Year	-

Cash/sh	7.00	P/FCF	-	EPS past 3/5Y	-	ROIC	-26.54%	52W Low	17.06 71.92%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.47% 4.94%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.46	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	25.06	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	66.67	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	25.06	EPS Q/Q	14.49%	SMA20	6.35%	Beta	1.46	Target Price	39.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	18.94%	Rel Volume	1.90	Prev Close	28.60

Employees	76	LT Debt/Eq	-0.02	Earnings	Nov 05	SMA200	23.04%	Avg Volume	123.87K	Price	29.33

IPO Date	Feb 06, 2026	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.69% -	Net Debt/EBITDA	3.79	Volume	235,587	Change	2.55%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-14-26	Initiated	Raymond James	Outperform	$39
Mar-03-26	Reiterated	Jefferies		$62

Latest News· Times ET

Sep-10-26

Sep-10-2610:37AM

SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com

Sep-02-26

Sep-02-2604:00AM

SpyGlass Pharma to Participate in Upcoming Investor Conferencesglobenewswire.com

Aug-14-26

Aug-14-2604:57AM

This Aehr Test Systems Analyst Begins Coverage On A Bearish Note; Here Are Top 4 Initiations For FridayBenzinga

03:55AM

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More247wallst.com

Aug-06-26

Aug-06-2612:05PM

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.com

Jul-25-26

Jul-25-2610:02PM

Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?defenseworld.net

12:43AM

Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGPdefenseworld.net

Company

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Ownership

Total institutional ownership127.23%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		1
Gross Profit		-1
Selling, General and Administrative Excl. Other		12
Research and Development		29
Other Operating Expense		0
Operating Income		-41
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		2
Net Income Before Taxes		-40
Income Taxes		0
Consolidated Net Income		-40
Net Income From Continuing Operations		-40
Net Income		-40
EPS (Recurring)		-1.25
EPS (Basic, Before Extraordinaries)		-1.25
EPS (Diluted)		-1.25
EBITDA		-39
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		32
Market Capitalization		—
Operating Lease Expense		—

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.